Disease heterogeneity in amyotrophic lateral sclerosis poses a substantial challenge in drug
development. Categorization based on clinical features alone can help us predict the …

In the last few years, our understanding of disease molecular mechanisms underpinning
ALS has advanced greatly, allowing the first steps in translating into clinical practice novel …

There is an ever growing literature on frontotemporal dysfunction in motor neuron diseases,
but the practical caveats of using imaging to evaluate extra-motor changes and linking …

Background Primary lateral sclerosis (PLS) is traditionally regarded as a pure upper motor
neuron disorder, but recent cases series have highlighted cognitive deficits in executive and …

The arrival of genotype-specific therapies in amyotrophic lateral sclerosis (ALS) signals the
dawn of precision medicine in motor neuron diseases (MNDs). After decades of academic …

Background: Motor neuron diseases (MNDs) are progressive neurodegenerative disorders
characterized by motor impairment and non-motor symptoms. The involvement of the …

Background ALS patients with hexanucleotide expansion in C9orf72 are characterized by a
specific clinical phenotype, including more aggressive disease course and cognitive …